公开(公告)号：US20140309241A1

公开(公告)日：2014-10-16

申请号：US14238790

申请日：2012-08-14

申请人： Jianfeng Li ,  Guanghui Tian ,  Zhen Wang ,  Jin Suo ,  Xiangrul Jiang ,  Zheng Liu ,  Xiaojun Yang ,  Zhu Xix ,  Xianguo Zhao ,  Weilang Zhu ,  Hualiang Jiang ,  Jingshan Shen

发明人： Jianfeng Li ,  Guanghui Tian ,  Zhen Wang ,  Jin Suo ,  Xiangrul Jiang ,  Zheng Liu ,  Xiaojun Yang ,  Zhu Xix ,  Xianguo Zhao ,  Weilang Zhu ,  Hualiang Jiang ,  Jingshan Shen

IPC分类号： C07D487/04

CPC分类号： C07D487/04 ,  C07B2200/13

摘要： The present invention relates to new salts of pyrazolopyrimidinone represented by formula (I), and pharmaceutically acceptable polymorph, solvate, hydrate, dehydrate, co-crystallization, anhydrous, or amorphous form thereof, the pharmaceutical compositions, and a pharmaceutical unit dosage form containing the same, wherein x represents organic or inorganic acids, preferable maleic acid, succinic acid, methanesulfonic acid, hydrochloric acid, etc. The invention further relates to co-crystals or complexes of compounds of pyrazolopyrimidinone and pharmaceutical compositions containing the same. The present invention also relates to a process for the preparation, use thereof and pharmaceutical preparation containing the salts or crystalline forms.

摘要翻译： 本发明涉及由式（I）表示的吡唑并嘧啶酮的新盐及其药学上可接受的多晶型物，溶剂化物，水合物，脱水，共结晶，无水或无定形形式，药物组合物和含有 相同的，其中x表示有机或无机酸，优选的马来酸，琥珀酸，甲磺酸，盐酸等。本发明还涉及吡唑并嘧啶酮化合物的共晶或络合物和含有它们的药物组合物。 本发明还涉及其制备方法，使用方法和含有盐或结晶形式的药物制剂。